全文获取类型
收费全文 | 10669篇 |
免费 | 727篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 56篇 |
儿科学 | 278篇 |
妇产科学 | 185篇 |
基础医学 | 1529篇 |
口腔科学 | 205篇 |
临床医学 | 1030篇 |
内科学 | 2393篇 |
皮肤病学 | 200篇 |
神经病学 | 857篇 |
特种医学 | 404篇 |
外科学 | 1634篇 |
综合类 | 92篇 |
一般理论 | 4篇 |
预防医学 | 832篇 |
眼科学 | 336篇 |
药学 | 659篇 |
中国医学 | 10篇 |
肿瘤学 | 742篇 |
出版年
2023年 | 36篇 |
2022年 | 162篇 |
2021年 | 278篇 |
2020年 | 122篇 |
2019年 | 214篇 |
2018年 | 285篇 |
2017年 | 185篇 |
2016年 | 195篇 |
2015年 | 231篇 |
2014年 | 297篇 |
2013年 | 465篇 |
2012年 | 712篇 |
2011年 | 740篇 |
2010年 | 423篇 |
2009年 | 365篇 |
2008年 | 646篇 |
2007年 | 700篇 |
2006年 | 624篇 |
2005年 | 699篇 |
2004年 | 624篇 |
2003年 | 573篇 |
2002年 | 578篇 |
2001年 | 121篇 |
2000年 | 137篇 |
1999年 | 143篇 |
1998年 | 137篇 |
1997年 | 125篇 |
1996年 | 86篇 |
1995年 | 100篇 |
1994年 | 84篇 |
1993年 | 91篇 |
1992年 | 93篇 |
1991年 | 109篇 |
1990年 | 84篇 |
1989年 | 86篇 |
1988年 | 73篇 |
1987年 | 71篇 |
1986年 | 51篇 |
1985年 | 55篇 |
1984年 | 63篇 |
1983年 | 55篇 |
1982年 | 55篇 |
1981年 | 48篇 |
1980年 | 45篇 |
1979年 | 26篇 |
1978年 | 30篇 |
1977年 | 30篇 |
1976年 | 20篇 |
1974年 | 20篇 |
1973年 | 21篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Véronique Diéras Jacques Bonneterre Valérie Laurence Marian Degardin Jean-Yves Pierga Marie-Edith Bonneterre Sandrine Marreaud Denis Lacombe Pierre Fumoleau 《Clinical cancer research》2005,11(17):6256-6260
PURPOSE: The purpose of this study was to investigate the safety and tolerability of MS209, a potent inhibitor of P-glycoprotein, when given in combination with docetaxel and to determine whether MS209 affects docetaxel pharmacokinetics. EXPERIMENTAL DESIGN: Patients with advanced solid malignancies were eligible for this phase I trial. Docetaxel as 1-hour infusion was given alone during the first cycle. MS209 was introduced as of cycle 2 and given orally 30 minutes after docetaxel infusion. The dose escalation scheme followed a modified Fibonacci model with six steps (docetaxel, 60-100 mg/m2 and MS209, 300-1,200 mg per body). RESULTS: A total of 30 patients were treated at five dose levels. Dose-limiting toxicities were febrile neutropenia, infection, stomatitis, dysphagia, and fatigue. The maximum tolerated dose was reached at level 5 (docetaxel, 80-MS: 1,200). Pharmacokinetic analysis failed to show a strong pharmacokinetic interaction between the two compounds, but at the highest dose levels, there is a trend to an increase of docetaxel AUC when this agent is given in combination with MS209. CONCLUSION: MS209 can be given in combination with docetaxel, with limited effect on docetaxel toxicity or pharmacokinetics. 相似文献
102.
Charles Butts Nevin Murray Andrew Maksymiuk Glenwood Goss Ernie Marshall Denis Soulières Yvon Cormier Peter Ellis Allan Price Ravinder Sawhney Mary Davis Janine Mansi Colum Smith Dimitrios Vergidis Paul Ellis Mary MacNeil Martin Palmer 《Journal of clinical oncology》2005,23(27):6674-6681
PURPOSE: To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and toxicity in patients with stage IIIB and IV non-small-cell lung cancer (NSCLC). Secondary objectives included health-related quality of life (QOL) and immune responses elicited by L-BLP25. PATIENTS AND METHODS: Patients with an Eastern Cooperative Oncology Group performance status of 0 to 2 and stable or responding stage IIIB or IV NSCLC after any first-line chemotherapy were prestratified by stage and randomly assigned to either L-BLP25 plus best supportive care (BSC) or BSC alone. Patients in the L-BLP25 arm received a single intravenous dose of cyclophosphamide 300 mg/m2 followed by eight weekly subcutaneous immunizations with L-BLP25 (1,000 microg). Subsequent immunizations were administered at 6-week intervals. RESULTS: The survival results indicate a median survival time of 4.4 months longer for patients randomly assigned to the L-BLP25 arm (88 patients) compared with patients assigned to the BSC arm (83 patients; adjusted hazard ratio [HR] = 0.739; 95% CI, 0.509 to 1.073; P = .112). The greatest effect was observed in stage IIIB locoregional (LR) patients, for whom the median survival time for the L-BLP25 arm has not yet been reached compared with 13.3 months for the BSC arm (adjusted HR = 0.524; 95% CI, 0.261 to 1.052; P = .069). No significant toxicity was observed. QOL was maintained longer in patients on the L-BLP25 arm. CONCLUSION: L-BLP25 maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity. The survival difference of 4.4 months observed with the vaccine did not reach statistical significance. In the subgroup of patients with stage IIIB LR disease, a strong trend in 2-year survival in favor of L-BLP25 was observed. 相似文献
103.
104.
105.
106.
Aleksandr Kolchin Dmitrii Shuleiko Mikhail Martyshov Aleksandra Efimova Leonid Golovan Denis Presnov Tatiana Kunkel Victoriia Glukhenkaya Petr Lazarenko Pavel Kashkarov Stanislav Zabotnov Sergey Kozyukhin 《Materials》2022,15(10)
Ge2Sb2Te5 (GST225) looks to be a promising material for rewritable memory devices due to its relatively easy processing and high optical and electrophysical contrast for the crystalline and amorphous phases. In the present work, we combined the possibilities of crystallization and anisotropic structures fabrication using femtosecond laser treatment at the 1250 nm wavelength of 200 nm thin amorphous GST225 films on silicon oxide/silicon substrates. A raster treatment mode and photoexcited surface plasmon polariton generation allowed us to produce mutually orthogonal periodic structures, such as scanline tracks (the period is 120 ± 10 μm) and laser-induced gratings (the period is 1100 ± 50 nm), respectively. Alternating crystalline and amorphous phases at the irradiated surfaces were revealed according to Raman spectroscopy and optical microscopy studies for both types of structures. Such periodic modulation leads to artificial optical and electrophysical anisotropy. Reflectance spectra in the near infrared range differ for various polarizations of probing light, and this mainly results from the presence of laser-induced periodic surface structures. On the other hand, the scanline tracks cause strong conductivity anisotropy for dc measurements in the temperature range of 200–400 K. The obtained results are promising for designing new GST225-based memory devices in which anisotropy may promote increasing the information recording density. 相似文献
107.
108.
109.
Ekoukou D Khuong-Josses MA Ghibaudo N Mechali D Rotten D 《European journal of obstetrics, gynecology, and reproductive biology》2008,140(2):212-217
Objectives
To assess the risk of vertical transmission in HIV-infected pregnant women undergoing diagnostic amniocentesis, and to identify possible predictive factors.Study design
This was a single center retrospective study. The records of 330 HIV-infected pregnant women booked in our antenatal clinic from 31 January 2001 to 31 January 2006 were analyzed. Women who actually underwent diagnostic amniocentesis (“amniocentesis performed” group) were compared to those eligible for amniocentesis but who did not undergo the procedure (“amniocentesis withheld” group).Results
During the time period, 318 liveborn babies were delivered (9 HIV infected (2.8%)). Thirty-four women (35 fetuses) were eligible for diagnostic amniocentesis. Amniocentesis was performed in 11 (32.4%) of these women (12 fetuses, none infected among the 9 liveborns) and withheld in 23 (67.6%) women. Among the 19 liveborn babies in this latter group, 1 (5.3%) was infected. There was no statistical difference in vertical transmission rate between the whole cohort of HIV-infected pregnant women and the group of women eligible for amniocentesis; or between the women who actually had or did not have an amniocentesis.The women who did undergo amniocentesis all received highly active antiretroviral combination therapy with three drugs; all but two had an undetectable HIV viral load, only one had immunosuppression and none had HCV co-infection.Conclusion
No vertical transmission was observed in a group of nine liveborn babies after amniocentesis performed in selected HIV-infected pregnant women. In the presence of high genetic risk during pregnancy, amniocentesis can be considered after proper patient counselling. 相似文献110.